Codexis offers biocatalyst products and services, and Codex biocatalyst panels and kits enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.
The company’s platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe.
Piper Sandler has a $14 target price on Codexis stock. The consensus target is $10.93, and shares traded at $3.10 on Friday.
Ginkgo Bioworks
This microcap biotech has strong upside potential for investors looking for ideas in the space. Ginkgo Bioworks Holdings Inc. (NYSE: DNA) develops a platform for cell programming.
The company’s platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products and pharmaceuticals.
Earlier this year Ginkgo Bioworks announced a partnership with Boehringer Ingelheim. The two companies will leverage Ginkgo’s natural product discovery capabilities to accelerate the discovery and development of novel therapeutic molecules to address diseases with high unmet patient needs that are out of reach of conventional drug discovery.
Raymond James has set a $5 target price, and Ginkgo Bioworks stock has a consensus target of $4.24. On Friday, the stock traded at $2.00.
908 Devices
This is another Cathie Wood portfolio stock that also has the potential to be a huge winner. 908 Devices Inc. (NASDAQ: MASS) provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial biotech, forensics and adjacent markets. It operates in the Americas, Europe, the Asia Pacific and elsewhere.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
